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R E S E A R C H A R T I C L E
Bidirectional GPR119 AgonismRequires Peptide YY and
Glucose forActivity inMouseandHumanColonMucosa
Iain R. Tough,1 Sarah Forbes,1 Herbert Herzog,2 Robert M. Jones,3
Thue W. Schwartz,4 and Helen M. Cox1
1King’s College London, Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology &
Neuroscience, London SE1 1UL, United Kingdom; 2Garvan Institute of Medical Research, Darlinghurst New
South Wales 2010, Sydney, Australia; 3Department of Medicinal Chemistry, Arena Pharmaceuticals, San
Diego, California 92121; and 4Section for Metabolic Receptology and Enteroendocrinology, Novo Nordisk
Foundation Centre for Basic Metabolic Research, University of Copenhagen, Copenhagen DK-2200,
Denmark
The lipid sensor G protein–coupled receptor 119 (GPR119) is highly expressed by enteroendocrine L-
cells and pancreatic b-cells that release the hormones, peptide YY (PYY) and glucagonlike peptide 1,
and insulin, respectively. Endogenous oleoylethanolamide (OEA) and the dietary metabolite, 2-
monoacylglycerol (2-OG), can each activate GPR119. Here, we compared mucosal responses with
selective, synthetic GPR119 agonists (AR440006 and AR231453) and the lipids, OEA, 2-OG, and N-
oleoyldopamine (OLDA), monitoring epithelial ion transport as a readout for L-cell activity in native
mouse and human gastrointestinal (GI) mucosae. We also assessed GPR119 modulation of colonic
motility in wild-type (WT), GPR119-deficient (GPR1192/2), and PYY-deficient (PYY2/2) mice. The
water-soluble GPR119 agonist, AR440006 (that cannot traverse epithelial tight junctions), elicited
responses, when added apically or basolaterally in mouse and human colonic mucosae. In both
species, GPR119 responses were PYY, Y1 receptor mediated, and glucose dependent. AR440006
efficacymatched theGIdistributionof L-cells inWT tissues butwas absent fromGPR1192/2 tissue.OEA
and 2-OG responses were significantly reduced in the GPR1192/2 colon, but OLDA responses were
unchanged. Alternative L-cell activation via free fatty acid receptors 1, 3, and 4 and the G
protein–coupled bile acid receptor TGR5 or by the melanocortin 4 receptor, was unchanged in
GPR1192/2 tissues. The GPR119 agonist slowed transit in WT but not the PYY2/2 colon in vitro.
AR440006 (intraperitoneally) slowedWT colonic and upper-GI transit significantly in vivo. These data
indicate that luminal or blood-borne GPR119 agonism can stimulate L-cell PYY release with paracrine
consequences and slower motility. We suggest that this glucose-dependent L-cell response to a gut-
restricted GPR119 stimulus has potential therapeutic advantage in modulating insulinotropic sig-
naling with reduced risk of hypoglycemia. (Endocrinology 159: 1704–1717, 2018)
Gprotein–coupled receptor (GPCR) 119 (GPR119)is a lipid metabolite sensor that exhibits affinity
for the endogenous anorectic lipid, oleoylethanolamide
(OEA), as well as metabolites of dietary triglycerides, such
as 2-monoacylglycerol (2-OG) (1). The receptor is highly
expressed by pancreatic b-cells and gastrointestinal (GI)
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Abbreviations: 2-OG, 2-monoacylglycerol; ANOVA, analysis of variance; ap, apical; bl,
basolateral; EC50, half-maximal effective concentration; FAAH, fatty acid amide hy-
drolase; FFA, free fatty acid; FFA1, free fatty acid receptor 1; FFA3, free fatty acid
receptor 3; FFA4, free fatty acid receptor 4; GI, gastrointestinal; GIP, glucose-dependent
insulinotropic peptide; GLP-1, glucagonlike peptide 1; GPCR, G protein–coupled receptor;
GPR119, G protein–coupled receptor 119; GPR1192/2, G protein–coupled receptor
119 deficient; IP, intraperitoneal; Isc, short-circuit current; KH, Krebs-Henseleit; LC, liquid
chromatography; LCFA, long-chain free fatty acid; m/z, mass-to-charge ratio; MC4,
melanocortin 4 receptor;MS,mass spectrometry;MS/MS, tandemmass spectrometry; OEA,
oleoylethanolamide; OLDA, N-oleoyldopamine; PYY, peptide YY; PYY2/2, peptide YY
deficient; SEM, standard error of themean; SGLT1, sodium/glucose cotransporter 1; t, time;
TER, transepithelial resistance; TRPV1, transient receptor potential vanilloid 1; VIP, vasoactive
intestinal polypeptide; WT, wild-type; a-MSH, a-melanocyte–stimulating hormone.
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enteroendocrine K-cells and L-cells (2–6). This relatively
restricted expression pattern translates potentially to
reduced risk of receptor-mediated side-effects; however,
low-level GPR119 expression in skeletal muscle may
perturb fatty acid metabolism, leading to dyslipidemia
(7). Cellular GPR119 Gas signaling raises intracellular
cyclic adenosine monophosphate levels, and in b-cells,
this leads to glucose-stimulated insulin release (2) and in
L- or K-cells, to hormone secretion, i.e., glucagonlike
peptide 1 (GLP-1), peptide YY (PYY), and glucose-
dependent insulinotropic peptide (GIP) (3, 8–10). Ad-
ditionally, the glucose dependence of GPR119-triggered
incretin release reduces the possibility of hypoglycemia
(3, 8–11). The maximization of GPR119 activity
through selective agonism, in combination with either
dipeptidyl peptidase 4 inhibition to stabilize released
hormones or with long-chain free fatty acid (LCFA)
activators of free fatty acid receptor 1 (FFA1) (12), offers
improved potential treatment of type 2 diabetes (1, 6,
13, 14). However, to minimize detrimental muscular
effects (7) a gut-restricted approach would be prefer-
ential, assuming that GPR119 is located on luminal
L-cell (and K-cell) membranes. Whether GPR119 is
trafficked to luminal [apical (ap)] or blood-borne (basal)
surfaces (or both) is unclear currently. Furthermore, the
GPR119 agonists available, to date, are lipophilic and
often lacking GPR119 selectivity (11). This and other
nutrient-sensing GPCRs may be differentially targeted,
and we have used native mucosal preparations that
retain mucosal polarity to determine the sidedness
of responses to, for example, acyl lipid mimetics,
LCFA-stimulated FFA1 and free fatty acid receptor
4 (FFA4) signaling, or L-amino acids that act via the
calcium-sensing receptor (8, 10, 15, 16). Each of these
nutrient mechanisms can be stimulated apically or
basolaterally, but the commercially available ligands
specific for GPR119, FFA1, or FFA4 are lipid soluble, so
are unlikely to be restricted to one surface. A primary aim
of this study was therefore to determine the sidedness of
GPR119 responses in murine and human GI mucosae
using a water-soluble agonist, AR440006.
Previously, the “first-in-class” GPR119 agonist
PSN632408 was used to characterize L-cell activation via
endogenous PYY release and stimulation, predominantly
of epithelial Y1 receptors. PSN632408 improved glu-
cose tolerance in wild-type (WT) mice, but this was
compromised in PYY-deficient (PYY2/2) mice (8).
Subsequently, a more potent, selective GPR119 agonist
(PSN-GPR119) was used to cause PYY, GLP-1, and GIP
secretion, and crucially, the GPR119 agonist retained
glucose-dependent efficacy in diabetic rat and mouse GI
mucosae (10). Interestingly, this agonist exhibited re-
duced efficacy comparedwith PSN632408 (8), raising the
possibility of GPR119 desensitization with more potent
ligands with incretin relevance. GPR119 also exhibits
high constitutive activity in transfected cells (2, 17, 18),
but the degree to which this occurs in native tissue has not
yet been established. A selective antagonist (AR436352)
inhibits GPR119 constitutive activity and GPR119 ago-
nism (17). SmallmoleculeGPR119 agonists, with improved
selectivity, are also now available and have been shown
to stimulate PYY, as well as GLP-1 release from L-cells
in culture (19) and in native mucosae (8, 10). The
similarity in cellular distribution of PYY-sensitive
Y1 and Y2 receptors in the human and mouse colon
is worthy of note (20–22), particularly in the context of
nutrient-stimulated L-cell activation (23), and thus,
resolving these mechanisms in mouse GI tissues has
translational impact.
Locally produced lipids, such as OEA, activate
GPR119 at micromolar concentrations in recombinant
cells (24, 25), and in native tissues, this endogenous
activity would be indistinguishable from constitutive
GPR119 activity. The metabolism of endogenous OEA,
by the membrane fatty acid amide hydrolase (FAAH),
implicates the enzyme as an alternative target for am-
plifying incretin release with antidiabetic potential. The
availability of selective FAAH inhibitors (e.g., URB597)
(25) thus enables the interrogation of endogenous OEA
mechanisms in native tissues, including those from
knockout mice [GPR119 deficient (GPR1192/2)]. In-
terestingly, the hypophagic effects of OEA appear to be
independent of GPR119 (26), whereas its stimulation of
L-cell GLP-1 release (and that of AR231453 and 2-OG) is
significantly impaired in GPR1192/2 enteric cultures
(27). GPR1192/2 mice fed a standard diet have been
reported to exhibit normal glucose-stimulated insulin
release and GLP-1 secretion, but they lack sensitivity to
the GPR119 agonist AR231453 (2, 3), including its at-
tenuation of gastric emptying (28). A recent description
of a b-cell-specific GPR1192/2 mouse described normal
acute glucoregulatory responses (29), indicating that
GPR119 signaling in L-cells is likely to be the primary site
of lipid GPR119-mediated sensing. Therefore, we also set
out to establish the specificity of GPR119 signaling in
native mucosae from the mouse and human GI tract and
whether FAAH inhibition would amplify GPR119 sig-
naling in the mouse colon.
Given the growing significance of intestinal GPR119
signaling in glucoregulation, we determined the selec-
tivity of three lipids [OEA, 2-OG, andN-oleoyldopamine
(OLDA)], comparing their activities with those of
AR231453 and a water-soluble synthetic agonist,
AR440006, in GI tissues fromWT andGPR1192/2mice,
including the GPR119 antagonist, AR436352 (17). We
show that GPR119 activation on the luminal (ap) or the
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blood-borne [basolateral (bl)] surfaces is L-cell PYY
mediated and that these GPR119-specific responses are
glucose dependent in the WT mouse GI tract and in
human colonic mucosa.
Materials and Methods
Animals
All animal experimentation and care were conducted in
compliance with UK Home Office regulations [Animals (Sci-
entific Procedures) Act 1986] and were approved by the local
Ethics Committees in King’s College London and the University
of Copenhagen (Animal Experimental Inspectorate of the
Danish Minister of Justice: Project Number 13.242). WT adult
mice (12 weeks or older, of either sex) and the background
strain of C57BL/6J (GPR119+/+ and GPR1192/2) mice or the
mixture of C57BL/6-129SvJ (PYY+/+ and PYY2/2) mice were
used as indicated.Mice were housed conventionally in open-top
cages under a 12-hour light-dark cycle (0700 to 1900 hours) at
20 to 24°C and 55% (610%) humidity with free access to
standard chow (Rat and Mouse No.3 Breeding diet; Special
Diets Services, Braintree, UK) and tap water.
Measurement of short-circuit current across mouse
or human mucosal preparations
Mucosae from different regions of the GI tract of WT,
GPR1192/2, or PYY2/2 mice or normal human colon were
prepared, bathed in Krebs-Henseleit (KH) buffer, and voltage
clamped at 0mV inUssing chambers, as described previously (8,
20, 30). Human colon specimens were obtained from con-
senting patients undergoing elective bowel resection surgery for
cancer of the large bowel (as approved by the Research Ethics
Committee of Guy’s and St Thomas’ National Health Service
Foundation Trust). Vectorial ion transport was measured as
short-circuit current (Isc; microamps divided by centimeters
squared), and once initial baseline Isc and transepithelial re-
sistance (TER; +1.0 mV for 5 seconds every 250 seconds)
measurements had been made, drugs were added to the ap or bl
reservoir, as indicated. GPR119 antagonist pretreatment oc-
curred 15 minutes before addition of the secretagogue, vaso-
active intestinal polypeptide (VIP; 10 nM, bl), followed by a
single concentration only of a ligand, e.g., GPR119 agonist (ap
or bl). These ligand-induced reductions in Isc were measured for
20 minutes before a control PYY (10 nM, bl) addition. En-
dogenous PYY mediation of GPR119 activity was determined
using optimized blocking concentrations of the competitive Y1
antagonist (BIBO3304, 300 nM, bl) and/or Y2 antagonist
(BIIE0246, 1 mM, bl) (31). In glucose-sensitivity studies, mouse
colonic mucosa was bathed either with KH containing glucose
(11.1 mM) on both sides, or adjacent preparations were bathed
with KH, inwhich glucose was replaced bymannitol (11.1mM)
in either the ap or the bl reservoir (8, 10, 16, 30). As a control,
blockade of the apically directed sodium/glucose cotransporter
1 (SGLT1) was confirmed using ap phloridzin (50 mM). The
electrogenic response to phloridzin (a reduced Isc) was absent
when mannitol replaced glucose in the ap reservoir only. Ad-
ditionally, the effect of phloridzin (50 mM, ap) and phloretin
(100 mM, both sides) on GPR119 signaling was tested by
pretreating descending colon mucosa with the SGLT1 and
glucose transporter 2 inhibitors, followed 15 minutes later by
VIP (10 nM, bl), then AR440006 (300 nM, ap), and finally,
PYY (10 nM, bl).
In time-course experiments with a maximal concentration
of AR440006 (1 mM) or agonists selective for FFA1 (TAK875,
3 mM) (16), FFA receptor 3 (FFA3; AR420626, 100 nM), or
FFA4 (Merck A, 10 mM); G protein–coupled bile acid receptor,
TGR5 (Merck V, 1 mM) (32) or GP-A (3 mM) (33), each drug
was added to either the ap or bl reservoir (10 minutes after 10
nM VIP). The resultant free fatty acid (FFA)/TGR5-induced
decreases in Isc were monitored for 20 minutes and data pooled
from four different WT (C57BL/6-129SvJ) colonic specimens.
Mucosal TER was recorded throughout and TER data pre-
sented at the time (t) of agonist addition (t = 0minute) compared
with that at the peak of each agonist response (t = 5 to 10
minutes).
Liquid chromatography–tandem mass spectrometry
To determine whether AR440006 crossed mucosal prepa-
rations during the GPR119 response, bathing fluid was sampled
at agonist addition (t = 0 minutes, control) and 10 minutes later
when AR440006 responses were maximal. Particulate matter
was removed and samples diluted in 0.1% formic acid in 50%
methanol for liquid chromatography (LC)–tandem mass spec-
trometry (MS/MS; Thermo Accela pump and autosampler
coupled to a Thermo LTQ XL ion trap mass spectrometer, LC
column: Thermo Hypersil Gold aQ column, 50 mm 3
2.1 mm 3 3 mm; Thermo Fisher Scientific, Waltham, MA).
Aliquots (10 mL) were analyzed for 10 minutes (flow rate
200 mL/min) in a gradient of 0.1% formic acid in water (A) and
0.1% formic acid in acetonitrile (B). The initial gradient con-
ditions were 5%B, held for 0.2minute, then increased to 95%B
at 3 minutes. Ninety-five percent B was maintained for 2
minutes, and the column was re-equilibrated at 5% B over 0.5
minute and held for 4.5 minutes (total run time 10 minutes).
Mass spectrometry [MS; full MS over mass range mass-to-
charge ratio (m/z) 350 to 550, full MS/MS of m/z 400 over
mass range m/z 110 to 450 at collision energy 15 Arb] used
electrospray with positive polarity, an ionization spray volt-
age (4000 V), capillary voltage (12 V), temperature (350°C),
and sheath gas flow (50 Arb). With the use of this method,
AR440006 exhibited a retention time of 4.2 minutes, and
product ion m/z 280 was used for AR440006 determination.
The relative abundance was calculated as the area of this peak in
samples from mucosa exposed to ap or bl AR440006 (at t =
0 and t = 10 minutes).
Measurement of basal rates and GPR119
agonist-stimulated colonic transit in vitro and in vivo
For colonic transit measurement in vitro, the entire mouse
colon was removed, measured, and photographed to provide
the initial position (t = 0 min) of fecal pellets from the cecal
junction to the rectum. Individual colons were placed in KH
buffer with vehicle (0.1% ethanol) PSN632408 (10 mM) for 20
minutes before a second photographwas taken to establish fecal
pellet transit, as described previously (31). For in vivo upper-GI
and colonic motility measurement, male and female WT mice
were acclimatized to handling for 3 days before experimentation
and were fasted overnight (for up to 16 hours). Vehicle (100 mL,
buffered saline) or AR440006 [30mg/kg, intraperitoneally (IP)]
was administered 10 minutes before rectal-bead insertion,
measuring the time to bead excretion as described previously
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(31, 34). Upper-GI transit was measured following intragastric
delivery of a charcoal meal, 15 minutes after IP vehicle or
AR440006 administration, recording the distance traveled by
the charcoal front in 30 minutes (and quoted as a percentage of
the total small intestinal length) (31, 34).
Statistical analyses
Results are expressed as means6 standard error of the mean
(SEM) fromnumbers of observations, as stated. These datawere
analyzed using GraphPad Prism (version 6.07; GraphPad
Software, La Jolla, CA), and statistical differences were iden-
tified using one-way analysis of variance (ANOVA) with
Dunnett (or Tukey) post hoc test, as appropriate. For single
comparisons between tissues from different genotypes or be-
tween vehicle and drug in vivo, Student unpaired t test was used,
and in all cases, P , 0.05 was considered statistically different.
Materials
BIBO3304 and BIIE0246 were purchased from Tocris
(Bristol, UK), PSN632408 and OEA were from Cayman
Chemical (Ann Arbor, MI), and tetrodotoxin and a-melanocyte–
stimulating hormone (a-MSH) were from Abcam Bio-
chemicals (Cambridge, UK). PYY was purchased from Generon
(Slough, UK) andVIP fromAnaSpec (Freemont, CA). AM1638,
AR231453, AR420626, AR435707, AR436352, AR440006,
Merck A, TAK875, and Merck V were provided by R.M.J. and
T.W.S. All other chemicals were purchased from Sigma-Aldrich
(Poole, UK).
Results
Basal electrophysiological parameters of differentGI
mucosae from mice of different genotypes
Mucosal preparations fromWT andGPR1192/2mice
were compared, specifically their baseline Isc and TER
values (Supplemental Table 1). WT-ascending colon Isc
levels were higher than those of other GI areas, whereas
jejunum and descending colon Isc levels were higher
in GPR1192/2 compared with corresponding WT tis-
sues. Additionally, TER values were significantly higher
in ascending and descending colon mucosae from
GPR1192/2 vs WT mice.
Comparison of the lipid and synthetic GPR119
agonism in the WT and GPR1192/2 mouse colon
The first-in-class water-soluble agonist AR440006
elicited responses with similar kinetics when added ei-
ther apically (Fig. 1A) or basolaterally (Fig. 1B), as ob-
served previously with the lipophilic GPR119 agonist
PSN632408 (8). LC-MS/MS analysis of ap and bl sam-
ples, 10 minutes after addition of AR440006 to either
surface, showed that only trace amounts of the drug
permeated across the tissue (Supplemental Fig. 1) at a
time when the mucosa was responding maximally. The
estimated concentration of AR440006 in the oppo-
site compartment, 10 minutes after drug addition, was
;2 nM, i.e., approximately the threshold concentration
for this drug. This indicates that GPR119 receptors are
located on both epithelial domains, i.e., facing the lumen
(apically) and the lamina propria (basolaterally), and that
GPR119 activation by luminal stimuli or lipids, present in
the lamina propria, is equally capable of depolarizing
L-cells. Next, a comparison of the potency and efficacy
of small molecule GPR119 agonists (AR231453 and
AR435707) (12), AR440006, and three lipids (OEA, 2-
OG, and OLDA) was undertaken in distal colon mu-
cosa, where L-cells predominate. Ap or bl addition of all
but one agonist (AR231453) exhibited similar maxima
and overlapping response time courses. Interestingly,
AR231453 was more potent but appeared to be a partial
agonist, its efficacy reaching only 50%of that exhibited by
all of the other agonists (Fig. 1C and 1D and Table 1). The
half-maximal effective concentration (EC50) values for
agonists tested apically or basolaterally were similar
(Table 1).
GPR119 agonism (with AR compounds) was signifi-
cantly inhibited by pretreatment with the Y1 antagonist
BIBO3304, and the residual GPR119 agonism was
abolished by inclusion of the Y2 antagonist (BIIE0246;
Fig. 1E, upper histogram). 2-OG responses were also
abolished by the combination of Y1 and Y2 blockers, as
well as by the GPR119 antagonist AR436352 (Fig. 1E,
lower histogram), confirming the GPR119 activity of 2-
OG. In contrast, responses to OLDA were unaffected
by either Y1/Y2 receptor antagonists or by GPR119
blockade (Fig. 1E, lower histogram), indicating a non-
GPR119 mechanism for this lipid’s mucosal response.
Importantly, the responses to AR231453 and OEA were
glucose sensitive (Fig. 1F), as seen previously for the
GPR119 agonism in rodent colon mucosae (8, 10). In-
ternal controls confirmed that replacement of ap glucose
with mannitol abolished the ability of the SGLT1 in-
hibitor, phloridzin, to reduce Isc levels (as SGLT1 is
apically located and Na+ coupled), whereas PYY re-
sponses were predictably glucose insensitive (Fig. 1F).
Phloridzin (50 mM, ap) pretreatment also significantly
inhibited AR440006 (300 nM, ap) responses (vehicle
controls:28.36 0.7mA $ cm22; +Phloridzin:22.06 0.6
mA $ cm22, n = 5, P , 0.001). The combination of
phloridzin (ap) and phloretin (both sides) abolished
AR440006 responses (20.86 0.5 mA $ cm22, n = 5, P,
0.001, compared with control GPR119 responses quoted
previously), whereas PYY (and VIP) responses were
unaffected by coincident SGLT1 and glucose transporter
2 inhibition (data not shown).
To establish specific loss-of-GPR119 function and show
sidedness of GPR119 receptors, we used GPR1192/2 tis-
sues and the water-soluble GPR119 ligand AR440006
(Fig. 2A). Bl a-MSH was included (as a control) to ac-
tivate melanocortin 4 receptors (MC4) that are also
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Figure 1. Small molecule and lipid-based GPR119 agonism in mouse-descending colon mucosa. (A) Time dependence of ap and (B) bl
AR440006 responses (1 mM, n = 4). (C) Concentration-response curves for three small molecule GPR119 agonists and (D) three lipids added to
either the ap or bl reservoirs. The horizontal, dashed, gray lines denote the maximal response to the GPR119 agonist, PSN632408 (ap), published
previously (8). (E) Upper histogram shows inhibition of the ap GPR119 agonism (3 nM AR231453, 30 nM AR435707, or 300 nM AR440006) by
Y1 and Y2 receptor blockade [300 nM BIBO3304 (BIBO) and 1 mM BIIE0246 (BIIE), respectively] compared with vehicle (Veh; 0.01% dimethyl
sulfoxide). In the lower histogram, ap 2-OG (3 mM), OEA (10 mM), or OLDA (300 nM) responses are differentially affected by pretreatment with
the GPR119 antagonist, AR436352 (10 mM, ap) or Y antagonists (BIBO and BIIE, as shown previously). (F) AR231453 (10 nM; upper histogram)
and OEA (10 mM; lower histogram) responses require the presence of ap glucose (Gluc). In both histograms, phloridzin (Phlor; 50 mM, ap) only
reduces Isc when glucose is present apically. Subsequent PYY (10 nM) responses are unaffected by replacement of glucose on either side. Each
point or bar is the means 6 1 SEM from n numbers (in parentheses). Statistical differences (ANOVA with Dunnett post hoc test) from controls are
identified as follows: *P , 0.05, **P , 0.01, and ***P , 0.001. Mann, mannitol; DIsc, change in Isc.
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expressed by L-cells (30) in four distinct GI areas (jeju-
num, terminal ileum, ascending, and descending colon;
Fig. 2B), and these peptide responses were compared in
WT and GPR1192/2 mucosae. The bl AR440006 ago-
nism was absent in GPR1192/2 tissues, whereas a-MSH
responses were unchanged in all GPR1192/2 tissues
(Fig. 2A and 2B). MC4 agonism was confirmed using the
MC4 antagonist, HS014 (30 nM), to block all a-MSH
responses (data not shown), thus indicating normal
MC4Gas signaling in L-cells of GPR1192/2mucosa. As
seen previously, the size of GPR119 andMC4 responses
was greatest in the distal colon (8, 30), following the
established pattern of increased L-cell frequency in the
distal large bowel. In GPR1192/2-descending colon
mucosa, all four small molecule GPR119 ligands
(namely, PSN632408, AR440006, AR435707, and
AR231453) lost considerable activity, as did OEA and
2-OG (Fig. 2C and 2D). In contrast, OLDA responses
were a similar size inWT andGPR1192/2 tissue (Fig. 2C
and 2D), and this lipid response is therefore not GPR119
mediated. OLDA has been suggested as an endogenous
transient receptor potential vanilloid 1 (TRPV1) ac-
tivator (35), but TRPV1 desensitization with capsaicin
had no effect on OLDA responses in mouse colon
mucosa (data not shown).
The competitive GPR119 antagonist, AR436352 (36),
raised basal Isc levels (Fig. 2E), revealing GPR119 tonic
activity in WT-descending colon mucosa. Subsequent ap
AR440006 responses were abolished (Fig. 2E). OEA
responses were also inhibited significantly by the
GPR119 antagonist [OEA (10 mM) + antagonist:25.06
1.0 mA/cm2 (n = 4) compared with OEA controls shown
in Fig. 2C (n = 4), P , 0.001]. GPR119 tone was absent
in GPR1192/2 tissue (Fig. 2F and 2G). Next, other
GPCR tonic activities were compared in the WT and
GPR1192/2 colon using proven competitive antagonists
selective for the MC4, Y1, or Y2 receptors. The MC4
antagonist HS014 revealed tonic MC4 activity (as seen
previously) (30) thatwas similar in theWTandGPR1192/2
colon (Fig. 2F and 2G). Y1 and Y2 tonic activities, revealed
by using a combination of the competitive Y1 antagonist
BIBO3304 and Y2 antagonist BIIE0246, were also un-
changed in GPR1192/2 mucosa (Fig. 2F and 2G), in-
dicating normal L-cell and endogenous PYY functions in
GPR1192/2 mucosa.
FAAH inhibition enhances GPR119 tone and Y1 tone
but not MC4 tone in colonic mucosa
The FAAH inhibitor URB597 has been shown to el-
evate OEA levels and amplify GPR119 signaling (25), so
it was important to establish whether FAAH inhibition in
mucosa resulted in enhanced GPR119 tonic activity.
First, bl addition of URB597 (3mM) significantly reduced
basal Isc levels in WT colon mucosa, and this effect was
absent in PYY2/2 tissue (Fig. 3A). Next, FAAH inhibition
amplified GPR119 tone in the WT colon (with 3 mM
URB597; Fig. 3B, left), and this tonic activity was absent
in the PYY2/2 colon (Fig. 3B, right). URB597 also am-
plified Y1 tone in the WT tissue, but it failed to do so in
PYY2/2 colon mucosa (Fig. 3C). In contrast, URB597
pretreatment had no effect on MC4 tone, revealed by the
MC4 antagonist HS-014 (Fig. 3D), but this tonic activity
was also absent in PYY2/2, as observed previously (30).
Thus, FAAH blockade amplified GPR119 and Y1 tonic
activities, implicating the potential involvement of en-
dogenous OEA in GPR119- and PYY-induced Y1 tone,
but not in MC4 tone. Notably, all three tonic mucosal
activities required the presence of endogenous PYY.
FFA1, FFA3, FFA4, and TGR5 signaling is similar in the
WT and GPR1192/2 colon
A number of FFA and bile acid GPCRs are expressed
by L-cells rather than the surrounding epithelia (37). We
Table 1. Agonist EC50 Values (With Confidence Limits and d.f.) Following Single Additions to Either the ap or
bl Side
Agonist (Side Added) EC50 95% Confidence Limits d.f. n Numbers
AR231453 (ap) 1.2 nM 0.7–2.2 nM 49 3–16
AR231453 (bl) 1.6 nM 0.9–2.8 nM 21 3–7
AR435707 (ap) 27.7 nM 16.1–47.7 nM 28 3–5
AR435707 (bl) n.d. — — 4
AR440006 (ap) 170.4 nM 37.0–784.5 nM 24 3–4
AR440006 (bl) n.d. — — 4
OLDA (ap) 251.0 nM 97.2–648.4 nM 23 3–4
OLDA (bl) 455.3 nM 121.0 nM–1.7 mM 21 3–4
2-OG (ap) 4.9 mM 184.4 nM–1.2 mM 25 3–6
2-OG (bl) 3.7 mM 159.3 nM–85.2 mM 22 3–4
OEA (ap) 14.7 mM 48.6 nM–4.4 mM 27 3–12
OEA (bl) 10.6 mM 181.6 nM–616.8 mM 19 3–7
Abbreviation: d.f., degrees of freedom; EC50, half-maximal concentration; n.d., not determined (as only two bl agonist concentrations were tested and,
critically, these responses were identical to their ap counterparts).
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Figure 2. Selectivity of small molecule agonists compared with three lipids in WT and GPR1192/2 intestinal and colonic mucosae. (A) Regional
variation of responses to the water soluble GPR119 agonist, AR440006 (1 mM; bl), in WT and GPR1192/2 jejunum, terminal ileum (T. Ileum),
ascending colon (A. colon), and descending colon (D. colon) mucosae. (B) Regional variation of a-MSH (1 mM; bl) responses in intestinal mucosae
from WT and GPR1192/2 mice. Responses to maximally effective concentrations of the small molecule GPR119 agonists, PSN632408 (PSN; 10
mM), AR440006 (006; 1 mM), AR435707 (707; 100 nM), and AR231453 (453; 10 nM), or the lipids, OEA (10 mM), 2-OG (30 mM), and OLDA
(30 mM), each added apically in (C) WT or (D) GPR1192/2-descending colon mucosa. (E) Endogenous GPR119 tone was revealed by the GPR119
antagonist AR436352 (10 mM; ap) that then abolished subsequent AR440006 (1 mM; ap) responses. (F) GPR119 antagonist AR436352 (1 mM;
bl), the MC4 antagonist HS014 (30 nM; bl), Y1 antagonist BIBO3304 (300 nM BIBO; bl), or Y2 antagonist BIIE0246 (1 mM BIIE; bl) revealed tonic
activities in WT colonic mucosa, but (G) only GPR119 tone was absent from GPR1192/2 mucosa. Values are the means 6 1 SEM with statistical
differences as shown: *P , 0.05, **P , 0.01, and ***P , 0.001 (Student t test), comparing responses in WT and GPR1192/2 tissues.
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set out to establish whether FFA receptor-induced L-cell
activation, specifically via FFA1, FFA3, or FFA4, or the
bile acid receptor TGR5 were inhibited in GPR1192/2
colon mucosa, using proven selective agonists. Single ap
agonist additions (using predetermined maximal con-
centrations that were comparable with equivalent bl
responses; Supplemental Fig. 2) each reduced Isc levels,
reminiscent of endogenous PYY, and none of these ap
responses were significantly altered in GPR1192/2 tissue
(Fig. 4). Two different FFA1 agonists were tested: the
prototypic TAK875 and AM1638, which was included,
as this FFA1 signaling occurs via coincident Gaq andGas
(32). In WT and GPR1192/2 tissue, AM1638 responses
were similar in size and were blocked by the Y1 antag-
onist (BIBO3304), rather than being Y2 mediated, as
pretreatment with the Y2 antagonist BIIE0246 had no
substantial effect on AM1638 responses (Fig. 4A). FFA3
and FFA4 agonism (using AR420626 and Merck A,
respectively) and the TGR5 agonism using Merck V
(Fig. 4D) (32) or GP-A (in the WT colon; Supplemental
Fig. 2) (33) were also similar in the WT and GPR1192/2
colon (Fig. 4B–4D), showing apparently normal L-cell
Gaq and Gas signaling in GPR1192/2 mucosa. In terms
of agonist time courses in the WT colon, the only subtle
difference between ap and bl signaling was seen with the
TGR5 agonists (Supplemental Fig. 2D). ApMerck V and
GP-A responses were slower in onset than their equiva-
lent bl time courses (significantly so between 2 and 4
minutes after Merck V addition). Ap GP-A efficacy was
also slower to peak and slightly blunted compared with
the bl agonism, although this was not statistically sig-
nificant. TERs did not change during any agonist re-
sponse (Supplemental Fig. 2), indicating maintained
epithelial barrier function throughout experimentation.
GPR119 signaling in the human colon is similar
pharmacologically to that in the WT mouse colon
In normal human colon mucosa, the GPR119 an-
tagonist, AR436352, blocked tonic activity (i.e., it raised
basal Isc levels when added either apically or basolat-
erally), as seen in WT mouse tissues, and it significantly
inhibited subsequent PSN632408 responses but had no
affect on PYY responses (Fig. 5A). As seen in mouse
tissue, AR440006 responses were a similar size, irre-
spective of the side on which this GPR119 agonist was
added (Fig. 5B), indicating that GPR119 is located on ap
and bl membranes in human colon mucosa. Notably,
AR440006 responses in the human colon are PYY me-
diated, and the combination of Y1 and Y2 antagonists
abolished the GPR119 agonism and subsequent PYY
Figure 3. FAAH inhibition with URB597 amplifies GPR119 and Y1 tones but not MC4 tone in the WT- or PYY2/2-descending colon. (A) The
effects of vehicle [0.3% dimethyl sulfoxide (DMSO)] or URB597 (at 1 or 3 mM, ap) on basal Isc levels in the WT colon (triplet of bars to left) and
PYY2/2 colon mucosa (right two bars). (B) Pretreatment with URB597 significantly amplifies (at 3 mM) GPR119 tone (revealed using GPR119
antagonist AR436352, 10 mM, ap) in WT (left) but not PYY2/2 tissue (right). (C) Y1 receptor signaling (after Y1 antagonist BIBO3304, 300 nM,
bl) is increased by URB597 but only in WT mucosa. (D) MC4 tone (revealed using MC4 antagonist HS014, 30 nM, bl) is unaffected by URB597
(3 mM, ap), and MC4 tone is absent in PYY2/2 tissue. Values are the means 6 1 SEM, and statistically significant differences from vehicle
controls (0.3% DMSO) were identified using ANOVA (with Dunnett post hoc test) and shown as: *P , 0.05, **P , 0.01, and ***P , 0.001,
whereas differences in tonic activities between WT and PYY2/2 are shown as: +P , 0.05 and +++P , 0.001.
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controls (Fig. 5B). Finally, AR231453, OEA, or OLDA
each reduced Isc levels to a similar degree after ap or bl
addition [Fig. 5C; for ap OEA responses, see (8)], again
consistent with the sensitivities observed in mouse
colon mucosa.
The effects of PYY or GPR119 knockout on colonic
motility and the GPR119 agonism in vitro and in vivo
Having shown that the GPR119 agonism in the mouse
and human colon results in endogenous PYY release and
consequent Y1 receptor signaling, we
next assessed the selective GPR119
agonism on mouse colonic transit in
vitro and in vivo. Fecal pellet move-
ment in vitro was significantly re-
tarded by GPR119 agonism (10 mM
PSN632408; Fig. 6A), but the same
stimulus had no effect on transit in the
PYY2/2 colon (Fig. 6A). The water-
soluble agonist AR440006 (1 mM)
also slowed transit significantly in the
WT colon and lost activity in the
PYY2/2 tissue (Fig. 6B). The basal rate
of fecal pellet transit was signifi-
cantly faster in the GPR1192/2 colon
compared with WT colonic transit
(Fig. 6C). In vivo measurement of bead
excretion in WT mice, administered IP
with AR440006 (30 mg/kg), revealed
that the GPR119 agonist more than
doubled the time taken for bead pas-
sage compared with saline controls,
indicating that the drug significantly
slowedWTcolonic transit (Fig. 6D). The
same IP dose of AR440006 also atten-
uated upper-GI transit significantly in
WT mice. Transit of the charcoal meal
was reduced from 90.5 6 4.1% (n = 5)
after vehicle to 76.86 2.1% (n = 5; P,
0.05) of the total small intestinal length
after treatment with AR440006.
Discussion
We have shown that a selective
GPR119 agonist, AR440006, or lipids
(OEA and 2-OG) elicit the same PYY-
mediated, antisecretory response, irre-
spective of the mucosal surface to
which the agonists are added. Being
water-soluble, traces of AR440006
only traverse epithelial tight junctions
(as determined by LC-MS/MS), and the
similar kinetics of this synthetic agonist’s ap and bl re-
sponses also indicate that GPR119 is located on both L-cell
domains. Importantly, this bidirectional GPR119 signaling
capacity was evident in human mucosa, and these results
raise the distinct advantage of luminal (or apically)-directed
GPR119 activation causing endogenous PYY and incretin
release. Restricting drug distribution should lower the risk
of GPR119 mechanism-based side-effects.
The structure-activity comparison showed AR435707
and AR440006 to be full agonists that were less potent
Figure 4. Comparison of selective FFA1, FFA3, FFA4, and TGR5 responses in GPR1192/2-
and WT-descending colon mucosa. (A) The selective FFA1 agonism with TAK875 (3 mM, ap)
or AM1638 (300 nM, ap) 6 Y1 antagonist BIBO3304 (300 nM; AM + BIBO) or 6 Y2
antagonist BIIE0246 (1 mM; AM + BIIE). (B) The FFA3 agonism (with AR420626, 100 nM), (C)
the FFA4 agonism (Merck A, 10 mM), and (D) the TGR5 agonist (Merck V, 1 mM) were each
added apically. Values are the means 2 1 SEM with statistical differences as shown: ++P ,
0.01 and +++P , 0.001, comparing AM1638 responses 6 BIBO in WT or GPR1192/2 tissues
(ANOVA with Dunnett post hoc test).
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than the prototypic GPR119 agonist, AR231453 (2, 11,
38). The efficacy and potency of each agonist were similar
for ap or bl application, indicating a similar GPR119
signaling capacity in each membrane domain. The lipids
2-OG and OEA also appeared to be full agonists at either
surface, and they were slightly less potent than OLDA.
Notably, all of the agonists tested, with the exception
of OLDA, were sensitive to the GPR119 antagonist
AR436352 (36), and their activities were absent in
GPR1192/2 tissue (where OLDA’s was unchanged),
indicating GPR119 as the primary target for all agonists
but not OLDA. In addition, all agonism bar OLDAs were
sensitive to Y1 and Y2 antagonists, indicating that all
responses (except OLDA’s) were PYY mediated. OLDA
also lacked activity at TRPV1 (35), and we infer that in the
mouse colon [an area lacking a correlation between
GPR119 and dopamine synthesis (35)] OLDA acts on
neither GPR119 nor TRPV1. The GPR119 antagonist,
AR436352, also blocked PSN632408 responses on either
surface in human colon mucosa, showing further, close
Figure 5. GPR119 tone and pharmacology in human colonic mucosa. (A) GPR119 antagonism (1 mM, AR436352), added to either ap or bl
surfaces, is compared with vehicle (0.1% dimethyl sulfoxide) and subsequent GPR119 agonism [10 mM PSN632408 (632)], followed by PYY
(100 nM) responses after either ap or bl AR436352. (B) AR440006 (3 mM) responses are similar when added to ap or bl reservoirs, and ap
responses are blocked by Y receptor antagonists [300 nM BIBO3304 and 1 mM BIIE0246 (after BIBO & BIIE)]. Subsequent PYY responses (100
nM, bl) are also abolished after Y antagonist addition. (C) A comparison of ap and bl responses to AR231453, OEA, or OLDA, and the dashed,
horizontal, gray “OEA ap” line denotes maximal responses to OEA (10 mM, ap), published in Cox et al. (8). Each bar is the means 6 1 SEM from
n numbers, as shown. Statistical differences (ANOVA with Dunnett post hoc test) from controls are identified as follows: *P , 0.05, **P , 0.01,
and ***P , 0.001.
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similarity with the GPR119 pharmacology obtained in
mouse mucosae.
Basal Isc levels in WT-ascending colon mucosa were
expectedly higher than those in other GI areas, given the
higher Na+ absorptive capacity of this proximal colonic
region (39). This pattern was replicated in GPR1192/2
tissues, with elevated Isc levels in GPR1192/2 jejunum
and descending colonmucosae, possibly as a result of loss
of substantial GPR119 inhibitory tone in these regions.
The other notable differencewas inGPR1192/2-ascending
and -descending colon TER that were slightly higher than
in WT mucosae, indicating raised epithelial resistance,
but of unknown origin. Otherwise, the mucosae from
these two genotypes were similar, revealing normal ep-
ithelial barrier function, and they were comparable with
the parameters published previously for mucosae from
the same range of GI areas (31, 40).
Previously, the GPR119 agonism has been shown to
improve oral glucose tolerance in lean and diabetic
rodents, and that glucose induces serosal secretion of in-
testinal PYY, GLP-1, and GIP (2, 3, 10). However, the
mucosal responses that we observed in the distal colon
were predominantly PYYmediated, and this is most likely
because GLP-1 (and GIP) responses are relatively small in
this region of the mouse colon (41) (Iain R. Tough and
Helen M. Cox, unpublished GIP data). Crucially, in our
2010 study, we observed GPR119-induced GLP-1 re-
sponses in human colonmucosa but onlywhenY1 andY2
receptors were blocked (8). Therefore, it is likely that GLP-
1 and PYY are coreleased, and their responses are co-
incident upon GPR119 stimulation in human mucosae,
but the lower levels of GLP-1 receptor expression in the
mouse colon limit GLP-1 signaling compared with the
more robust PYY-mediated Y1 epithelial mechanism in
this tissue (22, 23, 31, 40). Differential PYY and GLP-1
release is, however, also possible, given that the peptides
can be packaged in different vesicle populations within L-
cells (42), and this may also explain why certain ligands
(e.g., for FFA2) appear to act solely via PYY (34).
To minimize GPR119 desensitization in mucosae, we
added one agonist concentration per preparation and
monitored non-normalized responses for 20 to 30 min-
utes. Therefore, we were surprised to find that the most
potent ligand, AR231453, was a partial agonist com-
pared with the slightly less potent agonists AR435707
and AR440006 and the lipids OEA and 2-OG in mouse-
descending colon mucosa. In a previous study, also using
single additions, the potent agonist PSN-GPR119 also
exhibited partial efficacy (;50%) (10) compared with
PSN632408 (8) and other agonists tested in the current
study. Why AR231453 is partially active in native mouse
tissue when it apparently exhibits full agonism via Gas
signaling in isolated murine L-cells and when it binds
apparently to similar epitopes on the GPR119 receptor as
OEA (17, 38) have yet to be resolved. Nevertheless,
this agonist exhibited efficacy in vivo, reducing gastric
emptying (28), improving glucose tolerance in WT mice
and in b-cell-specific GPR119 knockouts (29), and
showing the functional significance of GPR119 incretin
signaling in glucoregulation. Importantly, Moss et al.
(27) showed that L-cell knockout of GPR119 abolished
elevations in plasma GLP-1 after oral gavage of an olive
and corn-oil mixture. Acute fat exposure stimulated GLP-1
secretion in lean humans (as well as increasing duodenal
GPR119 but not FFA1 or FFA4 expression), whereas
habitual consumption of polyunsaturated fatty acids was
negatively correlated with GPR119 expression (43).
Thus, GPR119 appears to be an early transcriptional
responder to duodenal fat, and our own studies show
clear PYY responses to acute luminal GPR119 agonists in
human colonic mucosa; thus, GPR119 is a likely lipid
sensor along the length of the human GI tract.
Figure 6. Transit is reduced by the GPR119 agonism in the WT
mouse colon in vitro and in vivo. (A) Incubation of the isolated
colon with PSN632408 (PSN; 10 mM) but not vehicle (Veh) slowed
fecal pellet propulsion in the WT tissue (+/+; black bars) but not in
the PYY2/2 colon (white bar). (B) Colonic transit in vitro was
retarded by AR440006 (006; 1 mM) in the WT colon, and this
activity was absent in PYY2/2 tissue. (C) Fecal pellet propulsion was
significantly increased in the GPR1192/2 (white bar) compared with
the WT colon (black bar). (D) AR440006 (30 mg/kg, IP) significantly
slowed WT colorectal transit in vivo compared with vehicle (100 ml
saline IP). Each bar is the means + 1 SEM from the n numbers
shown in parentheses. Statistical differences were identified either
using unpaired Student t test, +P , 0.05, or one-way ANOVA with
Dunnett post-test, **P , 0.01, for drug treatment comparisons
between the WT and PYY2/2 colon.
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GPR119 is constitutively active (17), especially when
signaling via Gas in recombinant cells (18) and in native
L-cells (27). Constitutive GPR119 activity may con-
tribute to the endogenous GPR119 tone that we ob-
served in the mouse and human colon using the GPR119
antagonist AR436352 (36). It is possible that locally
produced lipids, such as OEA, provide a degree of en-
dogenous ligand-activatedGPR119 activity (24, 44) and
subsequent PYY release. With the use of an FAAH
blocker at a concentration shown to elevate endogenous
OEA levels and to amplify GPR119 signaling (25), we
revealed enhanced GPR119 and Y1 tonic activities in
WT but not in PYY2/2 tissues following URB597 pre-
treatment. It is notable that the blocking of MC4, an-
other L-cell-expressed receptor (with the antagonist
HS-014) (30) revealed tonic MC4 activity that was
unaffected by ablation of GPR119 or by FAAH in-
hibition. We conclude that endogenous OEA may
contribute to GPR119 and Y1 tone, but it is not ap-
parently required for MC4 tone [for which the endog-
enous mediator(s) remain to be identified]. Y1 and Y2
tones were, however, present in the GPR1192/2 colon,
showing signaling downstream of L-cell activation; i.e.,
PYY responses were normal in the GPR1192/2 tissue.
Taken together, we conclude that several endogenous
mechanisms—GPR119 being one important pathway—
stimulate L-cells and PYY responses within mucosae and
notably, that this mechanism extends to retarding colonic
and upper-GI motility.
The activities of agonists specific for other GPCRs
known to be highly expressing on L-cells highlight the
breadth of signaling, with functional relevance in
enteroendocrine cells (23, 37). Selective FFA1 and FFA4
mucosal signaling (albeit at single agonist concentrations)
was similar in the WT and GPR1192/2 colon, and their
response time courses after ap or bl addition were co-
incident. These LCFA-activatable pathways are also
PYY, Y1 mediated and glucose sensitive (16), as is the
FFA2 agonism (34). The selective FFA3 agonismwas also
unchanged in the GPR1192/2 colon, but this short-chain
fatty acid sensor is markedly different from FFA2 and
other nutrient-sensing mechanisms discussed thus far.
Intestinal FFA3 signaling does not appear to be L-cell or
PYY/GLP-1 mediated. Instead, the FFA3 agonism (with
AR420626) involves enteric neurons (45) and is glucose
independent inmouse colonic mucosa (Iain R. Tough and
Helen M. Cox, unpublished data), and this mechanism
was also unaltered in the GPR1192/2 colon. Acute short-
chain fatty acid activation of FFA2 and FFA3 leads to
coincident L-cell and submucosal enteric neuron acti-
vation (Iain R. Tough and Helen M. Cox, unpublished
data). Interestingly, commensal microbes can also gen-
erate N-acyl amides with affinity for GPR119, so in
addition to its fat-sensing function, luminally directed
GPR119 may sense certain microbial metabolites (46).
Finally, we found that acute ap TGR5 responses with
Merck V were comparable in the WT and GPR1192/2
colon, but these responses exhibited a 2-minute latency
compared with the faster bl Merck V responses. A similar
latency was observed with ap administration of another
TGR5 agonist, GP-A [at the same concentration used by
Brighton et al. (33)], which exhibited a bl preference
measuring GLP-1 release from ileal mucosa, over a 60-
minute period. It is possible that these TGR5 agonists
cross GI mucosae to activate predominant basolaterally
located TGR5, but the peak epithelial responses that
we observed were not significantly different within 10
minutes, although ap GP-A responses were blunted.
Potentially, the sidedness of the TGR5 agonism may
resolve further over 1 hour or longer time periods, as
observed in vivo for peptide release following systemic,
rather than luminal, TGR5 agonist exposure (47). Nev-
ertheless, in our study, the acute L-cell signaling initiated
by the ap TGR5 agonism was consistent in WT and
GPR1192/2 colonic mucosa, as was FFA1, FFA3,
and FFA4 signaling.
In summary, our mucosal studies have found that ap
as well as bl GPR119 agonism have the potential to
stimulate L-cell PYY release with paracrine consequences
that extend to the slowing of upper-GI and colonic mo-
tility. We propose that this glucose-dependent L-cell
response to a gut-restricted GPR119 stimulus has thera-
peutic potential, either alone or in combination with
peptide-stabilizing drugs, in modulating insulinotropic
signaling with reduced risk of hypoglycemia.
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